Related Experiment Video
Updated: Mar 9, 2026
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
AB3-Loaded and Tumor-Targeted Unimolecular Micelles for Medullary Thyroid Cancer Treatment
Renata Jaskula-Sztul1, Guojun Chen2, Ajitha Dammalapati3
1Department of Surgery, School of Medicine University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Abstract:
Medullary thyroid cancer (MTC) is often resistant to standard therapies, emphasizing the need for the development of other treatments. A new histone deacetylase inhibitor, AB3, can effectively inhibit MTC cell proliferation in vitro. However, its poor aqueous solubility and stability, fast clearance, and lack of tumor targeting ability limit its in vivo application. Therefore, multifunctional unimolecular micelles were developed for targeted delivery of AB3 for MTC therapy. The unimolecular micelles exhibited a spherical core-shell structure, uniform size distribution, and excellent stability. AB3 was encapsulated into the hydrophobic core of the unimolecular micelles, thus significantly enhancing its aqueous solubility and stability. KE108, a somatostatin analog possessing high affinity to all five subtypes of SSTR, was used as an MTC-targeting ligand. In vitro cellular uptake analyses demonstrated that the KE108 exhibited superior targeting ability in MTC cells compared to octreotide, the first clinically used somatostatin analog. Moreover, the AB3-loaded and KE108-conjugated unimolecular micelles exhibited the best efficacy in suppressing MTC cell growth and tumor marker expression in vitro. Furthermore, AB3-loaded, KE108-conjugated micelles demonstrated the best anticancer efficacy in vivo without any apparent systemic toxicity, thereby offering a promising approach for targeted MTC therapy.
Insights
New unimolecular micelles effectively deliver the drug AB3 to target medullary thyroid cancer (MTC) cells. This targeted therapy enhances drug solubility and stability, showing promising in vivo anticancer efficacy with minimal toxicity.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Medullary thyroid cancer (MTC) often exhibits resistance to conventional treatments, necessitating novel therapeutic strategies.
- Histone deacetylase inhibitor AB3 shows in vitro efficacy against MTC but faces limitations in solubility, stability, and tumor targeting for in vivo use.
Purpose of the Study:
- To develop multifunctional unimolecular micelles for targeted delivery of AB3 to MTC.
- To enhance the aqueous solubility, stability, and tumor-targeting ability of AB3 for improved MTC therapy.
Main Methods:
- Development of unimolecular micelles with a core-shell structure for AB3 encapsulation.
- Conjugation of KE108, a somatostatin analog, as a targeting ligand for MTC cells.
- In vitro and in vivo evaluation of the efficacy and toxicity of AB3-loaded, KE108-conjugated micelles.
Main Results:
- Unimolecular micelles demonstrated enhanced aqueous solubility and stability of AB3.
- KE108 showed superior targeting of MTC cells compared to octreotide.
- AB3-loaded, KE108-conjugated micelles significantly suppressed MTC cell growth and tumor markers in vitro.
- These micelles exhibited potent in vivo anticancer efficacy with no apparent systemic toxicity.
Conclusions:
- Multifunctional unimolecular micelles offer a promising platform for targeted delivery of AB3 in MTC therapy.
- The developed nanocarrier system overcomes the limitations of AB3, improving its therapeutic potential.
- This approach represents a viable strategy for enhancing medullary thyroid cancer treatment outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:20Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...